These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 36516792)

  • 1. New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.
    Aguilar Diaz JM; Abulfathi AA; Te Brake LH; van Ingen J; Kuipers S; Magis-Escurra C; Raaijmakers J; Svensson EM; Boeree MJ
    Respiration; 2023; 102(2):83-100. PubMed ID: 36516792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.
    Garcia-Prats AJ; Starke JR; Waning B; Kaiser B; Seddon JA
    J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S101-S109. PubMed ID: 36314547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    Mok S; Roycroft E; Flanagan PR; Wagener J; Fitzgibbon MM
    J Antimicrob Chemother; 2023 Nov; 78(11):2637-2644. PubMed ID: 37740935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
    Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
    Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shortened tuberculosis treatment regimens: what is new?
    Silva DR; Mello FCQ; Migliori GB
    J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
    Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022].
    Yu JJ; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jan; 46(1):62-66. PubMed ID: 36617931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
    Buziashvili M; Davtyan H; Sereda Y; Denisiuk O; Gozalov O; Lomtadze N; Hovhannesyan A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs and perspectives for new anti-tuberculosis regimens.
    Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
    Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
    Harausz EP; Garcia-Prats AJ; Seddon JA; Schaaf HS; Hesseling AC; Achar J; Bernheimer J; Cruz AT; D'Ambrosio L; Detjen A; Graham SM; Hughes J; Jonckheere S; Marais BJ; Migliori GB; McKenna L; Skrahina A; Tadolini M; Wilson P; Furin J;
    Am J Respir Crit Care Med; 2017 May; 195(10):1300-1310. PubMed ID: 27854508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
    J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in antibiotic therapy for tuberculosis].
    Maitre T; Guglielmetti L; Robert J; Aubry A; Veziris N
    Rev Prat; 2024 Mar; 74(3):239-244. PubMed ID: 38551855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.
    Madzgharashvili T; Salindri AD; Magee MJ; Tukvadze N; Avaliani Z; Blumberg HM; Kempker RR; Lomtadze N
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):457-467. PubMed ID: 33347564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.